IL4 and asthma: This indicated a reduction in the Th2 effector subset after Smo-inhibitor treatment, as IL-4 is a key Th2 cytokine, and ST2 is an IL-33 receptor that is involved in the Th2 inflammatory response and asthma, which can also be used as a marker of Th2 identity (45, 46).